Last reviewed · How we verify
Sustained-Release Venlafaxine Hydrochloride
At a glance
| Generic name | Sustained-Release Venlafaxine Hydrochloride |
|---|---|
| Sponsor | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia (NA)
- Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Venlafaxine Hydrochloride Sustained-release Tablets in Patients With Major Depression Disorder (NA)
- Bioequivalence Study of Venlafaxine Hydrochloride Sustained-Release Capsules in Chinese Healthy Volunteers (NA)
- Accurate Clinical Study of Medication in Patients With Depression Via Pharmacogenomics (PGx) and Therapeutic Drug Monitoring (TDM) of Venlafaxine (PHASE4)
- A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive Disorder (PHASE2, PHASE3)
- Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder (PHASE3)
- Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: